BridGene Biosciences to Present at Hippo Pathway Targeted Drug Development Summit

SAN JOSE, Calif., May 18, 2023 /PRNewswire/ — BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high-value, traditionally undruggable targets, announced that Wolf Wiedemeyer, Ph.D., head of biology at BridGene, will be giving a presentation, titled “A Covalent TEAD Inhibitor with Exceptional Anti-cancer Activity & … Read more